Luft HS., Virtual Mentor. 14(5):407-10. doi: 10.1001/virtualmentor.2012.14.5.pfor1-1205., 2012 May 01
Associated Topics
Related Publications
Clopidogrel pharmacogenomics: next steps: a clinical algorithm, gene-gene interactions, and an elusive outcomes trial.
Gladding P1, Panattoni L, Webster M, Cho L, Ellis S.
JACC Cardiovasc Interv. 3(10):995-1000. doi: 10.1016/j.jcin.2010.08.012.
2010 Oct 01
JACC Cardiovasc Interv. 3(10):995-1000. doi: 10.1016/j.jcin.2010.08.012.
2010 Oct 01
The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
Panattoni LE.
J Health Econ. 30(1):126-45. doi: 10.1016/j.jhealeco.2010.09.004. Epub 2010 Oct 8.
2011 Jan 01
J Health Econ. 30(1):126-45. doi: 10.1016/j.jhealeco.2010.09.004. Epub 2010 Oct 8.
2011 Jan 01
Medicare annual preventive care visits: use increased among fee-for-service patients, but many do not participate.
Chung S, Lesser LI, Lauderdale DS, Johns NE, Palaniappan LP, Luft HS.
Health Aff (Millwood). 34(1):11-20. doi: 10.1377/hlthaff.2014.0483.
2015 Jan 01
Health Aff (Millwood). 34(1):11-20. doi: 10.1377/hlthaff.2014.0483.
2015 Jan 01
Utilization of cardiac monitoring tests in women with non-metastatic breast cancer treated with trastuzumab.
Shin J, Liang SY, Hassett MJ, Phillips KA, Haas JS.
Personalized Medicine. 10(7): 703-708.
2013 Jan 01
Personalized Medicine. 10(7): 703-708.
2013 Jan 01
Economic perspectives on personalized health care and prevention.
Phillips KA, Sakowski JA, Liang SY, Ponce NA.
Forum for Health Economics and Policy. 16(2):57–86.
2013 Sep 01
Forum for Health Economics and Policy. 16(2):57–86.
2013 Sep 01